Skip to main content
Equibles
WINT logo

WINT · Windtree Therapeutics Inc /De/ · Metrics

Track WINT — free

Use WINT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research WINT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.14 +0.03 (+24.55%) At close · Aug 21
Rebalance outlook locked
Going-concern doubt — flagged Nov 19, 2025

Substantial doubt about the company's ability to continue as a going concern.

“We do not have sufficient cash and cash equivalents as of the date of this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Nov 19, 2025
Market Cap
$3,370
Shares
33.71M
Volume · Aug 21 6.7M Avg daily vol (3M) 12.02M

WINT metrics

43 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.14
Market cap
$3,370

Price action

20 metrics
Price change (1W)
-73.5%
Price change (30D)
—
Price change (3M)
-81.7%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
205.5%
Annualized volatility (3M)
250.2%
Beta
—
RSI (14D)
23.5
Price vs SMA 50
-79.1%
Price vs SMA 200
—
Avg volume (3M)
12.02M
Relative volume
0.6
Average dollar volume
$9.66M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
33.71M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.0×
reciprocal yield 21,691.4%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,186,765.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
11,869.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2022-05-05

Profitability

9 metrics
Gross margin
—
Operating margin
-12,572.2%
Trailing 12 months
Net margin
-13,876.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$33.50M
Net income (TTM)
−$39.99M
Trailing 12 months
Diluted EPS (TTM)
$-876,150.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$14,740.21
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
$-608,383.45
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1,949.33

Growth

11 metrics
Revenue growth YoY
-85.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$731,000
Trailing 12 months
EPS growth YoY
-434.0%
Shares change YoY
+61.1%
Year over year · more shares
Revenue CAGR (3Y)
-54.1%
Revenue CAGR (5Y)
-41.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-250.2%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
−$14.49M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-68.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$204,000
Total assets
$15.98M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$15.12M
Capital expenditures (TTM)
$0
R&D (TTM)
$8.54M
SG&A (TTM)
$8.41M
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 946486 CUSIP 97382D600 Visit website